A phase 1 study of AGEN2373, a novel CD137 agonist antibody designed to avoid hepatoxicity, in patients with advanced solid tumors.
Year: 2023
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Minal A. Barve, Anthony W. Tolcher, Richard D. Carvajal, Benjamin Izar, Anthony B. El-Khoueiry, Diana L. Hanna, Ahmad A. Tarhini, Eric D. Whitman, Shailender Bhatia, Diwakar Davar, Jose Lutzky, Matthew H. Taylor, Monique Tello, Katherine Rosenthal, Anna Danielyan, Wai Ki Yip, James Song, David Savitsky, Dhan Chand, Joseph Elan Grossman
Institutions: Mary Crowley Cancer Research Center, Northwell Health, Columbia University Irving Medical Center, USC Norris Comprehensive Cancer Center, Moffitt Cancer Center, Atlantic Health System, University of Washington, Fred Hutch Cancer Center, UPMC Hillman Cancer Center, University of Miami, Sylvester Comprehensive Cancer Center, Providence Portland Medical Center, Agenus (United States)
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4379283538